Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers

Salvatore Iervolino, Matteo Nicola Dario Di Minno, Rosario Peluso, Mariana Lofrano, Anna Russolillo, Giovanni Di Minno, Raffaele Scarpa

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease activity (MDA) and those who did not. Results. Among 146 PsA subjects, 10 discontinued therapy before 3-month followup because of adverse events; thus 136 concluded the study. All clinical outcome measures changed significantly from T0 to T3. Erythrocyte sedimentation rate showed a significant reduction (p <0.001). C-reactive protein (CRP), serum cholesterol, and triglycerides showed no significant variation (p > 0.05). The prevalence of MetS and liver steatosis showed no significant differences between subjects achieving MDA and those who did not (p = 0.347 and 0.053, respectively). Patients achieving MDA at T3 were younger than those not achieving MDA (p = 0.001). A lower baseline tender joint count (p = 0.001), swollen joint count (p = 0.013), Bath Ankylosing Spondylitis Disease Activity Index (p = 0.021), and Ritchie index (p = 0.006) were found in subjects achieving MDA. Age (OR 0.896, p = 0.003) and Bath Ankylosing Spondylitis Functional Index (BASFI) (OR 0.479, p = 0.007) inversely predicted, whereas CRP (OR 1.78, p = 0.018) directly predicted, achievement of MDA at T3. Conclusion. In patients with PsA, age, CRP, and BASFI at the beginning of treatment were found to be reliable predictors of MDA after 3 months of TNF-α blocker therapy. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)568-573
Number of pages6
JournalJournal of Rheumatology
Volume39
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Psoriatic Arthritis
Tumor Necrosis Factor-alpha
Ankylosing Spondylitis
Baths
Fatty Liver
Joints
Therapeutics
Blood Sedimentation
Rheumatology
Comorbidity
Outcome Assessment (Health Care)

Keywords

  • Minimal disease activity
  • Predictors of response
  • Psoriatic arthritis
  • Tumor necrosis factor-α blocker

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Iervolino, S., Di Minno, M. N. D., Peluso, R., Lofrano, M., Russolillo, A., Di Minno, G., & Scarpa, R. (2012). Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. Journal of Rheumatology, 39(3), 568-573. https://doi.org/10.3899/jrheum.110763

Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. / Iervolino, Salvatore; Di Minno, Matteo Nicola Dario; Peluso, Rosario; Lofrano, Mariana; Russolillo, Anna; Di Minno, Giovanni; Scarpa, Raffaele.

In: Journal of Rheumatology, Vol. 39, No. 3, 03.2012, p. 568-573.

Research output: Contribution to journalArticle

Iervolino, S, Di Minno, MND, Peluso, R, Lofrano, M, Russolillo, A, Di Minno, G & Scarpa, R 2012, 'Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers', Journal of Rheumatology, vol. 39, no. 3, pp. 568-573. https://doi.org/10.3899/jrheum.110763
Iervolino, Salvatore ; Di Minno, Matteo Nicola Dario ; Peluso, Rosario ; Lofrano, Mariana ; Russolillo, Anna ; Di Minno, Giovanni ; Scarpa, Raffaele. / Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. In: Journal of Rheumatology. 2012 ; Vol. 39, No. 3. pp. 568-573.
@article{d14e0abe8cac4a9982416d4350117e26,
title = "Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers",
abstract = "Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease activity (MDA) and those who did not. Results. Among 146 PsA subjects, 10 discontinued therapy before 3-month followup because of adverse events; thus 136 concluded the study. All clinical outcome measures changed significantly from T0 to T3. Erythrocyte sedimentation rate showed a significant reduction (p <0.001). C-reactive protein (CRP), serum cholesterol, and triglycerides showed no significant variation (p > 0.05). The prevalence of MetS and liver steatosis showed no significant differences between subjects achieving MDA and those who did not (p = 0.347 and 0.053, respectively). Patients achieving MDA at T3 were younger than those not achieving MDA (p = 0.001). A lower baseline tender joint count (p = 0.001), swollen joint count (p = 0.013), Bath Ankylosing Spondylitis Disease Activity Index (p = 0.021), and Ritchie index (p = 0.006) were found in subjects achieving MDA. Age (OR 0.896, p = 0.003) and Bath Ankylosing Spondylitis Functional Index (BASFI) (OR 0.479, p = 0.007) inversely predicted, whereas CRP (OR 1.78, p = 0.018) directly predicted, achievement of MDA at T3. Conclusion. In patients with PsA, age, CRP, and BASFI at the beginning of treatment were found to be reliable predictors of MDA after 3 months of TNF-α blocker therapy. The Journal of Rheumatology",
keywords = "Minimal disease activity, Predictors of response, Psoriatic arthritis, Tumor necrosis factor-α blocker",
author = "Salvatore Iervolino and {Di Minno}, {Matteo Nicola Dario} and Rosario Peluso and Mariana Lofrano and Anna Russolillo and {Di Minno}, Giovanni and Raffaele Scarpa",
year = "2012",
month = "3",
doi = "10.3899/jrheum.110763",
language = "English",
volume = "39",
pages = "568--573",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers

AU - Iervolino, Salvatore

AU - Di Minno, Matteo Nicola Dario

AU - Peluso, Rosario

AU - Lofrano, Mariana

AU - Russolillo, Anna

AU - Di Minno, Giovanni

AU - Scarpa, Raffaele

PY - 2012/3

Y1 - 2012/3

N2 - Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease activity (MDA) and those who did not. Results. Among 146 PsA subjects, 10 discontinued therapy before 3-month followup because of adverse events; thus 136 concluded the study. All clinical outcome measures changed significantly from T0 to T3. Erythrocyte sedimentation rate showed a significant reduction (p <0.001). C-reactive protein (CRP), serum cholesterol, and triglycerides showed no significant variation (p > 0.05). The prevalence of MetS and liver steatosis showed no significant differences between subjects achieving MDA and those who did not (p = 0.347 and 0.053, respectively). Patients achieving MDA at T3 were younger than those not achieving MDA (p = 0.001). A lower baseline tender joint count (p = 0.001), swollen joint count (p = 0.013), Bath Ankylosing Spondylitis Disease Activity Index (p = 0.021), and Ritchie index (p = 0.006) were found in subjects achieving MDA. Age (OR 0.896, p = 0.003) and Bath Ankylosing Spondylitis Functional Index (BASFI) (OR 0.479, p = 0.007) inversely predicted, whereas CRP (OR 1.78, p = 0.018) directly predicted, achievement of MDA at T3. Conclusion. In patients with PsA, age, CRP, and BASFI at the beginning of treatment were found to be reliable predictors of MDA after 3 months of TNF-α blocker therapy. The Journal of Rheumatology

AB - Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease activity (MDA) and those who did not. Results. Among 146 PsA subjects, 10 discontinued therapy before 3-month followup because of adverse events; thus 136 concluded the study. All clinical outcome measures changed significantly from T0 to T3. Erythrocyte sedimentation rate showed a significant reduction (p <0.001). C-reactive protein (CRP), serum cholesterol, and triglycerides showed no significant variation (p > 0.05). The prevalence of MetS and liver steatosis showed no significant differences between subjects achieving MDA and those who did not (p = 0.347 and 0.053, respectively). Patients achieving MDA at T3 were younger than those not achieving MDA (p = 0.001). A lower baseline tender joint count (p = 0.001), swollen joint count (p = 0.013), Bath Ankylosing Spondylitis Disease Activity Index (p = 0.021), and Ritchie index (p = 0.006) were found in subjects achieving MDA. Age (OR 0.896, p = 0.003) and Bath Ankylosing Spondylitis Functional Index (BASFI) (OR 0.479, p = 0.007) inversely predicted, whereas CRP (OR 1.78, p = 0.018) directly predicted, achievement of MDA at T3. Conclusion. In patients with PsA, age, CRP, and BASFI at the beginning of treatment were found to be reliable predictors of MDA after 3 months of TNF-α blocker therapy. The Journal of Rheumatology

KW - Minimal disease activity

KW - Predictors of response

KW - Psoriatic arthritis

KW - Tumor necrosis factor-α blocker

UR - http://www.scopus.com/inward/record.url?scp=84857888495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857888495&partnerID=8YFLogxK

U2 - 10.3899/jrheum.110763

DO - 10.3899/jrheum.110763

M3 - Article

C2 - 22247361

AN - SCOPUS:84857888495

VL - 39

SP - 568

EP - 573

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -